Indian pharma company Sava Healthcare has announced that its DPI capsule manufacturing line has received approval from the Russian Ministry of Health (MOH). Sava said that it manufactures tiotropium, formoterol, salmeterol/fluticasone, and budesonide/formoterol DPIs for the Russian and CIS markets.
According to Sava, its Surendranagar facility, which also manufactures nasal sprays, is accredited by Health Canada and health authorities from several other countries, including Ukraine. The company also has a DPI formulation R&D center in Pune.
Sava Group Chairman Vinod Ramchandra Jadhav commented, “This endorsement of Sava commitment to meeting GMP guidelines is welcoming news and gives Sava access to Russian pharmaceutical market which is estimated at 22 billion USD growing by 10% out of which respiratory drug category stands on 2nd fastest growing segment.”
Read the Sava Healthcare press release.
